CRSP
Crispr Therapeutics AGNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.86B
P/E Ratio
—
EPS
$-6.17
Beta
1.74
52W High
$78.48
52W Low
$35.38
50-Day MA
$51.02
200-Day MA
$55.74
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
23.36
PEG Ratio
-0.21
About Crispr Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.
Fundamentals
| Revenue (TTM) | $4.10M |
| Gross Profit (TTM) | $-478.71M |
| EBITDA | $-531.08M |
| Operating Margin | -8933.00% |
| Return on Equity | -31.20% |
| Return on Assets | -14.10% |
| Revenue/Share (TTM) | $0.04 |
| Book Value | $18.83 |
| Price-to-Book | 2.68 |
| Price-to-Sales (TTM) | 1183.81 |
| EV/Revenue | 3203.02 |
| EV/EBITDA | 14.16 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 68.60% |
| Shares Outstanding | $96.45M |
| Float | $96.04M |
| % Insiders | 5.90% |
| % Institutions | 79.19% |
Historical Volatility
HV 10-Day
38.66%
HV 20-Day
50.41%
HV 30-Day
62.17%
HV 60-Day
59.03%
HV Rank
52.8%
Volatility is currently contracting
Analyst Ratings
Consensus ($82.24 target)
4
Strong Buy13
Buy9
Hold1
SellMore HEALTHCARE Stocks
Data last updated: 5/25/2026